Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.
Am J Hematol
; 89(12): 1121-31, 2014 Dec.
Article
em En
| MEDLINE
| ID: mdl-25088818
ABSTRACT
Core binding factor acute myelogenous leukemia (CBF AML) constitutes 15% of adult AML and carries an overall good prognosis. CBF AML encodes two recurrent cytogentic abnormalities referred to as t(8;21) and inv (16). The two CBF AML entities are usually grouped together but there is a considerable clinical, pathologic and molecular heterogeneity within this group of diseases. Recent and ongoing studies are addressing the molecular heterogeneity, minimal residual disease and targeted therapies to improve the outcome of CBF AML. In this article, we present a comprehensive review about CBF AML with emphasis on molecular heterogeneity and new therapeutic options.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Leucemia Mieloide Aguda
/
Heterogeneidade Genética
/
Transplante de Células-Tronco
/
Fatores de Ligação ao Core
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Am J Hematol
Ano de publicação:
2014
Tipo de documento:
Article